T-NeuroDx Announces AlzheimerGuard™, a Novel Blood-Based Biomarker Assay for Early Detection of Alzheimer’s Disease

AlzheimerGuard is a proprietary blood-based biomarker assay designed to detect Alzheimer’s disease years before clinical symptoms appear.

ALBUQUERQUE, NM, UNITED STATES, April 15, 2026 /EINPresswire.com/ -- T-NeuroDx, a biotechnology company focused on advancing early diagnostics for neurodegenerative disease, today announced the branding of AlzheimerGuard, a proprietary blood-based biomarker assay designed to detect Alzheimer’s disease years before clinical symptoms appear, representing a major step forward in the development of accessible early detection tools for Alzheimer’s disease.

The AlzheimerGuard assay detects proprietary hiT Cells™, a specific population of aberrant immune T cells in the blood stream that are associated with the mechanism of disease initiation and progression. The foundational research underlying the technology was led by Dr. Christopher Wheeler, Chief Science Officer of T-NeuroDx, and published in Proceedings of the National Academy of Sciences (PNAS) and showed that hiT Cells decline as Alzheimer’s disease progresses. Monitoring the cells through a simple blood test may allow clinicians and researchers to detect disease-related biological changes long before cognitive symptoms become apparent, providing a preclinical window of 13 to 20 years for intervention.

“Early detection is one of the most critical unmet needs in Alzheimer’s research,” said Michael Reed, CEO of T-NeuroDx. “AlzheimerGuard represents a revolutionary approach for identifying disease risk earlier and enabling new strategies for clinical trials, prevention, and treatment.”

T-NeuroDx has recently been awarded a Small Business Innovation Research (SBIR) grant, which is supporting the next phase of biomarker validation in a collaboration with the University of Southern California’s Alzheimer’s Therapeutic Research Institute (USC ATRI). Through this federally funded program, the company will analyze over 400 additional patient samples to further confirm the performance of the AlzheimerGuard assay and expand the underlying clinical dataset supporting its development. The resulting data will contribute to future peer-reviewed publications and help advance the diagnostic toward biomarker validation and clinical application.

“By expanding the dataset and validating this biomarker across a larger patient population, we are moving closer to providing clinicians and researchers with a powerful tool for early Alzheimer’s detection,” Dr. Wheeler said.

Additional results from the SBIR-supported research are expected to be published in the near future.

About T-NeuroDx
T-NeuroDx is a biotechnology company focused on developing innovative diagnostic tools to detect neurodegenerative diseases at their earliest stages. By combining advances in immunology, biomarker discovery, and translational medicine, the company aims to create accessible diagnostic solutions that support early intervention, improved clinical trials, and better outcomes for patients at risk of Alzheimer’s disease.

Michael Reed - CEO
T-NeuroDx
mreed@tneurodx.com
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.